03-30	Calliditas Therapeutics AB Presents Exploratory Biomarker and Post-Hoc Nefigard Analyses At the World Congress of Nephrology	CI
11-11	Calliditas Therapeutics Reports Safety Data for Setanaxib in Patients with Alport Syndrome At the American Society of Nephrology Kidney Week	CI
08/07/25	Hansa Biopharma Names New Chief Medical Officer	MT
09/06/25	Calliditas Therapeutics Presented at the 62nd European Renal Association Congress	CI
24/04/25	Hansa Biopharma Appoints Former Calliditas CEO to Same Role	MT
08/01/25	SHB retail savers had Investor in their top buys last year	FW
24/04/24	Calliditas Therapeutics AB Auditor Raises 'Going Concern' Doubt	CI

More news

Managers and Directors: Calliditas Therapeutics AB

Manager	Title	Age	Since
Fredrik Johansson DFI	Director of Finance/CFO	49	01/08/2017
Lars Stubberud CTO	Chief Tech/Sci/R&D Officer	62	01/01/2024
Krassimir Mitchev CTO	Chief Tech/Sci/R&D Officer	-	01/03/2019

Director	Title	Age	Since
Mark Hensley CHM	Chairman	43	-
Yoshikazu Aoki BRD	Director/Board Member	-	-
Masaya Etoh BRD	Director/Board Member	-	-

More insiders

Specialty & Advanced Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CALLIDITAS THERAPEUTICS AB	+0.87%	+0.68%	-	-	1.16B
MERCK & CO., INC.	+2.12%	+2.27%	+46.94%	+2.78%	285B
MERCK KGAA	+1.50%	+2.23%	+23.46%	-11.74%	66.18B
KYOWA KIRIN CO., LTD.	-0.99%	+4.84%	+0.89%	-9.65%	8.2B
HALOZYME THERAPEUTICS, INC.	+1.49%	+0.45%	+32.49%	+104.91%	8.18B
SK BIOPHARMACEUTICALS CO., LTD.	-3.86%	-8.87%	-11.52%	-4.31%	4.35B
YUHAN CORPORATION	-4.90%	-11.53%	-33.01%	+24.01%	3.56B
BETTA PHARMACEUTICALS CO., LTD.	-0.34%	+9.37%	+6.36%	+22.07%	3.64B
SUPERNUS PHARMACEUTICALS, INC.	+0.65%	+3.01%	+40.33%	+37.57%	2.58B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+1.83%	-0.11%	+8.77%	-25.66%	1.96B
Average	-0.15%	-0.26%	+12.74%	+15.55%	42.65B
Weighted average by Cap.	+1.80%	+0.40%	+39.57%	+2.58%

See all sector performances

Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.

Employees

222

Sector

Pharmaceuticals

More about the company